Endostatin and ST2 are predictors of pulmonary hypertension disease course in infants

J Perinatol. 2020 Nov;40(11):1625-1633. doi: 10.1038/s41372-020-0671-8. Epub 2020 May 4.

Abstract

Introduction: Pulmonary hypertension (PH) is a common comorbidity of cardiopulmonary disease. Endostatin, an inhibitor of angiogenesis, is elevated in neonates with lung disease. ST2 is a heart failure biomarker correlated with PH in adults. We hypothesized that these biomarkers may be useful in diagnosing PH and categorizing its severity in infants.

Methods: Endostatin, ST2, and NT-proBNP plasma concentrations from 26 infants with PH and 21 control infants without PH were correlated with echocardiographic and clinical features using regression models over time.

Results: Endostatin, ST2, and NT-proBNP concentrations were elevated in PH participants versus controls (p < 0.0001). Endostatin was associated with right ventricular dysfunction (p = 0.014), septal flattening (p = 0.047), and pericardial effusion (p < 0.0001). ST2 concentrations predicted right to left patent ductus arteriosus flow (p = 0.009). NT-proBNP was not associated with PH features.

Conclusions: Endostatin and ST2 concentrations were associated with echocardiographic markers of worse PH in infants and may be better predictors than existing clinical standards.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers
  • Ductus Arteriosus, Patent*
  • Echocardiography
  • Endostatins* / analysis
  • Female
  • Humans
  • Hypertension, Pulmonary* / diagnosis
  • Infant
  • Infant, Newborn
  • Interleukin-1 Receptor-Like 1 Protein
  • Male
  • Natriuretic Peptide, Brain
  • Peptide Fragments

Substances

  • Biomarkers
  • Endostatins
  • IL1RL1 protein, human
  • Interleukin-1 Receptor-Like 1 Protein
  • Peptide Fragments
  • Natriuretic Peptide, Brain